$1.77
0.0653.80%
Last update: May 13, 12:18 PM
Coherus Oncology Inc Stock Guidance
CHRSNASDAQ
Earnings: Q1 2026 Earnings were released on Mon May 11th, after the market close
Conference Call: The most recent conference call started at 5:00 PM, 2 days agoClick to view the webcast
Coherus Oncology (CHRS) last issued guidance on January 13, 2025 for fiscal year 2024. The company guided revenue in the range of $255.00M - $260.00M for the period.
Compared to prior guidance, Coherus Oncology raised its revenue forecast from a prior range of $49.00M - $54.00M.
Coherus Oncology has issued 4 guidance updates between November 6, 2023 and January 13, 2025. During this period, the company raised its outlook 2 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
Latest Guidance Date
Jan 13, 2025
Guidance Period
Full Year 2024
Revenue Guidance Range
$255.00M - $260.00M
Coherus Oncology Guidance History
Review all historical guidance issued by Coherus Oncology, including EPS and revenue forecasts across quarterly and annual periods.
Loading calendar...
FAQ
What is the most recent guidance for Coherus Oncology (CHRS)?
The most recent guidance for Coherus Oncology (CHRS) was reported on January 13, 2025 for the fiscal year 2024. Coherus Oncology forecasted revenue between $255.00M and $260.00M for the period.
What revenue range did Coherus Oncology (CHRS) guide for?
Coherus Oncology (CHRS) guided revenue in the range of $255.00M to $260.00M for the fiscal year 2024.
Did Coherus Oncology (CHRS) raise or lower guidance?
Coherus Oncology (CHRS) raised its revenue guidance from a prior range of $49.00M - $54.00M to $255.00M - $260.00M for the fiscal year 2024.
When did Coherus Oncology (CHRS) last issue guidance?
Coherus Oncology (CHRS) last issued guidance on January 13, 2025 for the fiscal year 2024.
